Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

CHICAGO -- Upfront surgery for advanced ovarian cancer failed to improve overall survival (OS) versus interval debulking but did improve progression-free survival (PFS) for the first time in a phase ...

BOSTON — Patients with non-BRCA gene mutations undergoing risk-reduction surgery to prevent tubo-ovarian cancers showed no signs of tubo-ovarian high-grade serous carcinoma or serous tubal ...

Obesity is associated with increased surgical complications in EOC, including wound infections and intestinal problems, but not with overall survival differences. Meta-analysis showed obesity linked ...

Declining cytoreductive surgery in advanced EOC is associated with significantly poorer survival outcomes compared to those who undergo the procedure. Sociodemographic factors, including race, age, ...

Comprehensive Genomic Profiling for Resectable Pancreatic Cancer: The Earlier the Better? Data from CHIVA randomized phase II trial (ClinicalTrials.gov identifier: NCT01583322) and Policlinico Gemelli ...

Ovarian cancer has the lowest survival rate of any women's cancer, killing roughly one thousand women in Australia every year. But now, there's a new blood test that offers hope for detection, and ...

Women with certain genetic mutations are at extremely high risk of ovarian cancer. Now, some researchers are trying a new ...